Table 3.

Best overall response in patients receiving BI 836826 plus ibrutinib

	BI 836826 dose
Patients with response, n (%)	100 mg n = 3	200 mg n = 3	Total N = 6
Overall response	2 (67)	3 (100)	5 (83)
CR	0	1 (33)	1 (17)
CRi	0	0	0
PR	2 (67)	2 (67)	4 (67)
PR-L	0	0	0
Stable disease
Progressive disease	1 (33)	0	1 (17)

CR complete response, CRi complete response with incomplete marrow recovery, OR overall response (CR + CRi + PR + PR-L), PR partial response; PR-L partial response with lymphocytosis